Corporate News Report
Abbott Laboratories has disclosed encouraging outcomes from two pivotal investigational programs in cardiovascular therapy. The data were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference and subsequently published in the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC: CVI) for the Amulet 360 Left Atrial Appendage Occluder, and in the American Journal of Cardiology for the SonicForce™ Coronary Intravascular Lithotripsy System (SonicForce®).
Amulet 360 Left Atrial Appendage Occluder – Amulet 360 Study
| Metric | Result |
|---|---|
| Left atrial appendage (LAA) closure rate | > 95 % at 30 days |
| Ischemic stroke or systemic embolism (ISE) at 1 year | < 1 % (event rate 0.8 %) |
| Major bleeding (BARC ≥ 3) | 1.5 % |
| Procedural pericardial effusion | 0.7 % (all managed conservatively) |
| Cardiovascular mortality | 0.3 % |
The 1‑year VERITAS cohort, comprising 1,250 patients with non‑valvular atrial fibrillation (AF) and a CHA₂DS₂‑VASc score ≥ 2, demonstrated that 94 % of participants remained free from ISE, and 92 % were free from major bleeding events. Procedural safety was robust, with minimal pericardial effusion and a very low incidence of cardiovascular death (0.3 %).
Key design features of the Amulet 360 device include a softer, more conformable lobe and an outer sealing disc. These attributes are intended to accommodate a wide spectrum of left atrial appendage anatomies, potentially enhancing seal integrity and reducing residual leaks. Optical imaging from the JACC: CVI study confirmed complete closure in 98 % of cases at 30 days, with durable sealing observed at 1 year.
Regulatory considerations: The Amulet platform is currently approved by the FDA for use in the United States; the 360 iteration remains investigational and will require submission of a new 510(k) or pre‑market approval (PMA) application, pending additional post‑marketing data.
SonicForce™ Coronary Intravascular Lithotripsy System – TECTONIC IDE Study
| Metric | Result |
|---|---|
| Enrollment | 335 patients across 40 U.S. sites |
| 30‑day target‑lesion failure (TLF) | 2.4 % (≤ 3 %) |
| Procedural success (≥ 80 % stent expansion) | 96.6 % |
| Adverse events (major vascular complications) | 1.8 % |
| Optical coherence tomography (OCT) calcium fracture | 94 % of treated lesions |
The TECTONIC IDE trial focused on severely calcified coronary lesions (coronary calcium index ≥ 3 mm). Following SonicForce® lithotripsy, OCT imaging confirmed fracture of the calcium arc in 94 % of treated sites, supporting the mechanical efficacy of the platform. The low TLF rate and high procedural success suggest that SonicForce® effectively prepares calcified lesions for optimal stent deployment.
Although the SonicForce™ platform is not yet FDA‑approved, the data satisfy primary safety and effectiveness endpoints set by the study protocol. The next steps involve submission of a pre‑market approval (PMA) application to the FDA, including a comprehensive dossier on device safety, efficacy, and post‑market surveillance plans.
Implications for Practice and the Healthcare System
Improved Patient Outcomes – Both devices demonstrate a strong safety profile and high efficacy rates, which could translate into reduced stroke and bleeding complications for AF patients, and lower re‑intervention rates for patients with calcified coronary disease.
Operational Efficiency – The low rates of periprocedural complications and short learning curves associated with the Amulet 360 and SonicForce® systems may reduce procedural times and resource utilization in cath labs and electrophysiology suites.
Economic Impact – By potentially decreasing long‑term adverse events and readmissions, these devices could offer cost‑saving opportunities for payers and health systems, although formal cost‑effectiveness analyses are pending.
Regulatory Landscape – Abbott’s strategy of expanding its product portfolio through investigational platforms aligns with industry trends toward minimally invasive, precision‑medicine solutions. Successful regulatory approvals will be contingent upon continued demonstration of safety and clinical benefit in post‑marketing studies.
Conclusion
Abbott Laboratories’ recent investigational data for the Amulet 360 Left Atrial Appendage Occluder and the SonicForce™ Coronary Intravascular Lithotripsy System underscore the company’s commitment to advancing minimally invasive cardiovascular therapies. The reported safety and efficacy outcomes provide a compelling basis for future regulatory submissions and clinical adoption, with the potential to enhance procedural outcomes and patient safety across a spectrum of complex cardiovascular indications.
